The development and testing of high-impact combination therapies to produce powerful and compelling clinical data is at the core of Vicus’s business strategy. Therapy proof of concept, in turn, will lead to the out-licensing, continued development, and ultimate commercialization of our products

Our strategy of developing novel therapies comprised of well-understood FDA-approved drugs enables us to offer patients potentially breakthrough therapies that have already been proven safe and compatible with life-extending chemo, radiation, and surgical therapies.

Our business model of intensive collaboration with leading medical and surgical oncologists ensures our products are designed to fit within their clinical practices and treatment plans for their patients.

Vicus is currently sponsoring, at multiple sites, clinical trials for advanced lung cancer patients who are incurring severe weight loss. If you are physician and interested in further information, please email clinicalinfo@vicustherapeutics.com.